Related Experiment Video
Updated: Jan 4, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
13.2K
Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer
Xinning Wang1, Gopolakrishnan Ramamurthy2, Aditi A Shirke3
1Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. james.basilion@case.edu xxw171@case.edu.
Cancer Research
|November 14, 2019
Summary
A new photodynamic agent improves prostate cancer surgery by enabling better tumor visualization and eliminating residual cancer cells. This dual-action approach enhances surgical precision and reduces recurrence, offering a promising new treatment option.
Area of Science:
- Oncology
- Surgical Technology
- Photodynamic Therapy
Background:
- Prostate cancer recurrence after surgery is common, often due to positive margins.
- Improved visualization and adjuvant therapies are needed for effective prostate cancer resection.
Purpose of the Study:
- To evaluate a targeted photodynamic agent for image-guided surgery (IGS) and adjuvant photodynamic therapy (PDT) in prostate cancer.
Main Methods:
- Utilized a prostate-specific membrane antigen (PSMA)-targeted photodynamic agent (PSMA-1-Pc413).
- Assessed the agent's fluorescence for IGS and its efficacy in PDT for tumor ablation.
- Evaluated tumor recurrence and survival rates in an animal model.
Main Results:
- PSMA-1-Pc413 selectively highlighted PSMA-expressing tumors, improving visualization during surgery.
- IGS with PSMA-1-Pc413 led to more complete tumor resection compared to white light surgery.
- Subsequent PDT significantly reduced tumor recurrence and extended survival, also identifying lymph node metastasis.
Conclusions:
- PSMA-1-Pc413 serves as a dual-action agent for both IGS and PDT in prostate cancer surgery.
- This approach enhances tumor margin visualization and eliminates residual cancer cells, including in lymph nodes.
- Offers a potential new treatment strategy to improve surgical outcomes for prostate adenocarcinoma.
